Status:
COMPLETED
Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer
Lead Sponsor:
Vanderbilt-Ingram Cancer Center
Collaborating Sponsors:
United States Department of Defense
Conditions:
Renal Cell Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
This study will assess whether DNA released by kidney cancer into the blood stream and urine of patients can be used to monitor tumor burden and tumor response to treatment in patients receiving immun...
Detailed Description
Primary Objective: \- Evaluate tumor cell free (cf)DNA as a dynamic marker of response to immuno-oncology (IO) therapy Exploratory Objective: \- Collect data on somatic mutations in cfDNA to gain i...
Eligibility Criteria
Inclusion
- Renal Cell Carcinoma with clear cell component
- Stage IV
- Receiving IO-containing regimen
- Measurable disease per RECIST 1.1
Exclusion
- Active cancer (exclusion criteria only for healthy patient cohort)
Key Trial Info
Start Date :
January 6 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2023
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT04883827
Start Date
January 6 2021
End Date
December 1 2023
Last Update
October 22 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Tennessee Valley Health Care System
Nashville, Tennessee, United States, 37212
2
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
3
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030